The Effects of Multi-focal tDCS on Motor-cognitive Dysfunctions in Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

The Effects of Multi-focal Transcranial Direct Current Stimulation (tDCS) on Motor-cognitive Dysfunctions and Freezing of Gait in Patients With Parkinson's Disease: A Randomized Controlled Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02656316
• Other study ID #: TASMC-15-NIR-710-CTIL
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 2017
• Est. completion date: January 2020

Study information

• Verified date: October 2019
• Source: Tel-Aviv Sourasky Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current RCT aims to establish the therapeutic potential of tDCS for freezing of gait (FOG) and motor-cognitive dysfunctions in PD. As noted, FOG is often unresponsive to pharmacological and other treatments, especially in the advanced stages of the disease. While it is likely that tDCS will provide symptomatic relief, we will also explore, via secondary outcomes, the potential for tDCS to modify disease progression. Support for this possibility stems from the likely mechanisms of action of tDCS.

Description:

The current study aim to establish the therapeutic potential of tDCS for freezing of gait (FOG) and motor-cognitive dysfunctions in Parkinson's Disease (PD). FOG phenomenon is often unresponsive to pharmacological and other treatments, especially in the advanced stages of the disease. While it is likely that Transcranial direct current stimulation (tDCS) will provide symptomatic relief, we will also explore, via secondary outcomes, the potential for tDCS to modify disease progression. Support for this possibility stems from the likely mechanisms of action of tDCS.

Based on strong rationale and preliminary findings in previous works, the objectives of the current proposal are to conduct a prospective multi-center, double-blinded, stratified controlled randomized clinical trial, comparing real multifocal tDCS to sham stimulation. The main aim:

• To demonstrate the "short-term" and the longer-term effects of tDCS on FOG severity and frequency.

Participants: A total of 85 patients will be recruited (Hoehn and Yahr Stage 1-3.5) who suffer from FOG, as measured by the new FOG questionnaire (NFOG-Q) and as demonstrated in response to a FOG provoking protocol, who are on stable medications, who have no contraindications to tDCS, and who are between the ages of 40-80. Patients with DBS will not be included.

tDCS intervention: Subjects will be randomized to receive either a real or sham tDCS intervention. Each intervention will consist of 10, 20-minute treatments completed over 2 consecutive weeks (i.e., 5 per week), following previously established protocols. A single, weekly "maintenance" treatment will then be provided for the following 12 weeks (note: for depression, maintenance tDCS is most often provided once every two weeks; we will take a more conservative approach here in this first long-term study for FOG in PD).

Participants will continue taking their regular medications, and treatments will take place in the "ON" medication state (approximately at the same time of day for each treatment). The real tDCS intervention will simultaneously target both the M1 leg area and the the dorsolateral prefrontal cortex (DLPFC), in the brain hemisphere contralateral to the more affected side of the body, as determined by the summation of the motor symptoms on The unified Parkinson's disease rating scale (UPDRS). Current will be applied using an array of 8 sponge electrodes and the StarStim tDCS device and software (Neuroelectrics, Inc). For this protocol, the placement and current delivered through each electrode has been optimized using the Neuroelectrics StimWeaver® Stimulation Optimization Service . In case of bilateral symptom symmetry, tDCS will target the left M1 and DLPFC. For the sham intervention, the same electrode placement and stimulation parameters will be used; however, current will only be applied for the first 60 seconds of the stimulation session. This is a reliable control as sensations arising from tDCS diminish considerably after the first minute of stimulation. At the end of each treatment session, participants will complete a short questionnaire to assess potential side-effects. At the end of the entire intervention, participants will be asked to state if, in their opinion, they received the real or sham intervention.

Outcome measures: The primary outcome will be the number of FOG episodes measured in the lab when subjects undergo a validated FOG-invoking protocol, after the initial 2-week intervention and at the final study point, similar to that proposed by Ziegler et al. Briefly, this protocol includes situations that have been shown to provoke FOG. Patients will be asked to sit, to stand up and to walk to a a mark on the floor. They will perform two 360° turns, clockwise and counter-clockwise. Then, the patients will be asked to open a door and walk through it, turn outside, and come back to their chair. Secondary outcomes of FOG will include FOG duration and the new FOG questionnaire (NFOG-Q). This FOG-provoking protocol will take place in both the ON and OFF medication state and higher values (worse) of FOG will be used as the primary outcome measure (in secondary analyses, we will examine ON and OFF FOG separately).

Additional secondary measures will test the influence of tDCS on other motor, cognitive or motor-cognitive functions related to PD and FOG. Secondary outcomes related to motor function, which are likely to be affected by changes in M1 excitability, will include gait speed (usual walking), Timed Up & Go scores, UPDRS motor scores, and level of activity over 7 days using portable, lightweight, water-proof sensors. Secondary measures of executive function, which are hypothesized to be responsive to tDCS of the DLPFC, will include the Trail Making test (TMT) parts A and B, and a previously validated computerized neuropsychological battery that provides normalized scores for executive function and attention (and memory). Dual-tasking gait speed (i.e., walking while performing a serial subtraction test) will assess motor-cognitive interactions. Functional near infra-red spectroscopy (available in Boston and Tel Aviv) will assess frontal activation during dual-tasking walking; this reflects the subjects ability to handle cognitive loading and has been associated with FOG. Finally, the PDQ-39 will evaluate quality of life.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 85
• Est. completion date: January 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 90 Years

Eligibility

Inclusion Criteria:

Inclusion criteria: patients diagnosed with PD, with Hoehn and Yahr Stage between 1-3.5, who suffer from FOG, as measured at screening by the previously validated new FOG questionnaire (NFOG-Q), whose medications have not changed within 1 month of the study and are not anticipated to change during the study, are able to walk independently, and who are between the ages of 40-80 inclusive.

Exclusion Criteria:

Subjects who show no FOG during testing in the lab in response to a FOG provoking protocol, any diagnosed psychiatric or other neurological disorder, stroke, unbalanced and high blood pressure, pregnancy, participation in any clinical trial in the last three months, unwillingness to be randomized; implanted with deep brain stimulation, pacemakers, intracranial electrodes, implanted defibrillators or any other prosthesis; or a perceived inability to complete the study. Additional exclusion criteria related to tDCS safety will include a personal or family history of epilepsy, the use of neuro-active drugs, or risk of metal fragments in the eyes or head.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• Active tDCS
In this group subjects will receive 20 min of treatment.
• Sham tDCS
In this group subjects will receive 20 min of sham stimulation.

Locations

Country	Name	City	State
United States	Institute for Aging Research	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (3)

Leite J, Gonçalves OF, Carvalho S. Facilitative effects of bi-hemispheric tDCS in cognitive deficits of Parkinson disease patients. Med Hypotheses. 2014 Feb;82(2):138-40. doi: 10.1016/j.mehy.2013.11.021. Epub 2013 Dec 1. — View Citation

Weiss A, Herman T, Giladi N, Hausdorff JM. New evidence for gait abnormalities among Parkinson's disease patients who suffer from freezing of gait: insights using a body-fixed sensor worn for 3 days. J Neural Transm (Vienna). 2015 Mar;122(3):403-10. doi: 10.1007/s00702-014-1279-y. Epub 2014 Jul 29. — View Citation

Zhou J, Hao Y, Wang Y, Jor'dan A, Pascual-Leone A, Zhang J, Fang J, Manor B. Transcranial direct current stimulation reduces the cost of performing a cognitive task on gait and postural control. Eur J Neurosci. 2014 Apr;39(8):1343-8. doi: 10.1111/ejn.1249 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in frequency and severity of the freezing of gait phenomenon	Clinical assessment of freezing of gait: Gait tasks to provoke FOG (e.g. gait trajectory with dual tasking).	short (two weeks) after treatment and long term following (11 weeks) after treatment
Secondary	Changes in cognitive performance	The NeuroTrax software uses tests of cognitive performance that measure similar cognitive functions to traditional paper-based tests.	short (two weeks) after treatment and long term following (11 weeks) after treatment
Secondary	Immediate change in gait mesurments	Gait speed and variability will be assessed under usual and dual task conditions and while negotiating physical obstacles, using a sensorized 7 meter carpet (PKMAS) and wearable body fixed sensors. These measures will be compared to baseline performance.	short (two weeks) after treatment and long term following (11 weeks) after treatment